Pneumococcal Vaccines Market Analysis till 2026

Pneumococcal Vaccines Market (Product - Synflorix, Prevenar-13, PCV 13, V114, PCV-20, PCV-10, PPSV-23; Distribution Channel - Wholesalers (pharmacy channel), Specialized Companies, Public Authorities; Sector - Public, Private) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026

Global Pneumococcal Vaccines Market - Snapshot

Vaccination is one of the most cost-effective and safest ways to prevent diseases. Pneumococcus is one of the major causes of blood infection, pneumonia, sinusitis, meningitis, and otitis media. It is also a leading infectious disease. However, it can be prevented with the help of vaccination. Majority of countries have pneumococcal vaccines in their national immunization program for children aged under 1 year. Increase in pneumococcal diseases due to causative serotype drives the need for vaccines with broader coverage. Hence, demand for new pneumococcal vaccines with wider serotype coverage is rising.

pneumococcal vaccines industry

Despite the availability of antibiotic therapy against pneumococcal disease, it remains a significant cause of death among people with increased susceptibility such as the elderly and people suffering from immunosuppressive conditions or chronic illness. However, prevalence of pneumococcal disease has declined in countries that introduced pneumococcal conjugate vaccines (PCV). Meanwhile, efforts are underway to introduce pneumococcal vaccines in other countries as well. Companies also plan to introduce new and affordable PCVs, especially for the developing countries. There has also been an increase in investment in research and development to develop new vaccines at lower cost.

The global pneumococcal vaccines market has been segmented based on product type, distribution channel, sector, and region. In terms of product type, the global market has been classified into Synflorix, Prevenar-13, PCV 13 (pipeline), V114 (Merck), PCV-20 (Pfizer), PCV-10 (SII), and PPSV- 23. Each of the product segments has been divided into pediatric and adults. Based on distribution channel, the global market has been categorized into wholesalers (pharmacy channel), specialized companies, public authorities, and others. In terms of sector, the global pneumococcal vaccines market has been bifurcated into private and public. Based on region, the global market has been segmented into North America, Europe, Asia Pacific, Latin America, and Rest of the World.

In terms of product type, Prevenar-13 dominated the global market in 2017, accounting for 77.3% share. Prevenar-13 is Pfizer, Inc.’s largest brand, which has been one of the most widely adopted 13-valent PCV vaccines across the world. However, higher cost of the vaccine and entry of new vaccines are projected to hamper sales from 2018 to 2026.

Based on distribution channel, the wholesalers (pharmacy channel) segment dominated the global pneumococcal vaccines market in 2017. Vaccine distribution in Europe and some countries in Asia Pacific follows a traditional pharmaceutical supply chain, and wholesalers are dominant in these countries. However, shortage of vaccines and difficulty in accessing essential vaccines in several countries have led to the entry of public authorities in the overall supply and distribution of vaccines. Hence, the wholesalers segment is expected to lose market share from 2018 to 2026. Increase in participation by regional and national governments along with non-profit organizations for availability, supply, and distribution of pneumococcal vaccines in emerging countries is anticipated to boost the growth of the public segment between 2018 and 2026.

In terms of sector, the private segment dominated the global pneumococcal vaccines market in 2017. The U.S., the U.K., Germany, and other major countries in Europe, along with emerging markets such as India are dominated by the private sector engaged in procurement, distribution, and pricing of pneumococcal vaccines. Entry of non-profit organizations such as GAVI, UNICEF, and WHO is projected to result in higher procurement of vaccines in terms of volume (doses procured) by the public sector. However, involvement of these authorities in price negotiations of sourced vaccines from manufacturers is likely to lead to lower share of the public sector in terms of revenue (US$ Mn) of the global pneumococcal vaccines market from 2018 to 2026.

In terms of region, the global pneumococcal vaccines market has been segmented into North America, Europe, Latin America, Asia Pacific, and Rest of the World. North America dominated the global market in 2017, accounting for 57.9% share owing to strong sales of Prevenar-13 in the U.S. Pneumococcal conjugated vaccine (PCV) has been part of routine vaccine immunization in Canada and the U.S. since 2000. These countries have also witnessed highly-effective results since the vaccine was introduced. Investments by government organizations and private companies have also increased for the promotion of vaccination and research & development of new vaccines. North America has also emerged as a primary center for several vaccine manufacturers. PCV is also a part of vaccination programs in countries such as the Netherlands, Germany, Slovakia, Albania, Greece, and Serbia. Increase in incidence of pneumococcal diseases in countries in APEJ also presents an opportunity for companies producing pneumococcal vaccines. Brazil is witnessing a significant increase in pneumococcal diseases. Hence, various programs are being introduced in Brazil to increase vaccine coverage.

Major players operating in the global pneumococcal vaccines market include Pfizer, Inc., Merck & Co., Inc., SK Chemicals, Serum Institute of India Pvt. Ltd., Chengdu Institute of Biological Products Co., Ltd., GlaxoSmithKline plc, Sanofi, and Walvax Biotechnology Co., Ltd.

Continuous Progress in Conjugate Vaccine Development Boosts Pneumococcal Vaccines Market

The growth in the pneumococcal vaccines market has been largely spearheaded by continuous progress in conjugate vaccine development. The invasive as well non-invasive pneumococcal disease have been a major cause of morbidity in children and toddlers. High-income countries have been careful about conducting and supporting nationwide immunization programs provide protection against Streptococcus pneumoniae infections. On the other hand, low- and middle-income countries (LMICs), where the mortality is high in infants and toddlers, vaccination strategies have failed to provide protection due to the compromised resource settings. On the other hand, in high income countries, pneumococcal vaccination programs have led to development of herd immunity. As a result, strides in the pneumococcal vaccines market have led to substantial reduction of morbidity and mortality from invasive pneumococcal disease. However, in both these settings, the market has been witnessing an unmet need due to numerous factors: lack of access to optimal vaccine formulations and lack of understanding of immunological markers. To overcome the various limitations, market players are exploring innovative approaches and novel formulations. A case in point is growing focus of vaccine manufacturers on country-specific serotype-specific immunogenicity in developing vaccine formulations. Ongoing research pertaining to protein-based vaccines is expected to bring some of the promising product lines.

The current pandemic is being defined by Sars-CoV-2 virus infections and the rise in case loads in several countries across the world. The debilitating impact the pandemic has been making on the human health has challenged the existing healthcare infrastructure of even the most developed nations. The vaccination programs have received a new impetus from continuous efforts by governments, in collaboration with industry players, to make Covid-19 vaccines make available to public at large. The vaccines are currently viewed as the most powerful strategy in combating the morbidity and mortality of the novel coronavirus. Ongoing research in vaccine development are exploring new strategies on war-footing pace to unveil more efficacious formulations that can help develop herd immunity in the worldwide population. All these approaches are also influencing the growth of the pneumococcal vaccines market.

The global pneumococcal vaccines market has been segmented as below:

by Product Type

  • Synflorix
    • Pediatric
    • Adult
  • Prevenar-13
    • Pediatric
    • Adult
  • PCV 13 (pipeline)
    • Pediatric
    • Adult
  • V114 (Merck)
    • Pediatric
    • Adult
  • PCV-20 (Pfizer)
    • Pediatric
    • Adult
  • PCV-10 (SII)
    • Pediatric
    • Adult
  • PPSV- 23
    • Pediatric
    • Adult

by Distribution Channel

  • Wholesalers (pharmacy channel)
  • Specialized Companies
  • Public Authorities
  • Others

by Sector

  • Public
  • Private

by Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • Italy
    • France
    • Spain
    • Belgium
    • Rest of Europe
  • Asia Pacific
    • India
    • China
    • Japan
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Rest of the World
    • Middle East
    • Africa

    1. Preface 
         1.1. Report Scope and Market Segmentation 
         1.2. Research Highlights

    2. Assumptions and Research Methodology 
         2.1. Assumptions and Acronyms Used
         2.2. Research Methodology

    3. Executive Summary
         3.1. Global Pneumococcal Vaccines Market Size (US$ Mn) and Distribution, by Region, 2018 and 2026
         3.2. Global Pneumococcal Vaccines Market: Market Snapshot, 2016

    4. Market Overview
         4.1. Overview
         4.2. Global Pneumococcal Vaccines Market Size (US$ Mn) Forecast, 2016–2026
         4.3. Global Pneumococcal Vaccines Market Outlook
         4.4. Approved & Pipeline Products Snapshot

    5. Market Dynamics
         5.1. Drivers 
                5.1.1. Government participation in design & implementation of comprehensive vaccination programs
                5.1.2. Increase in investments by public & private players in R&D of conjugate pneumococcal vaccines
         5.2. Restraints
                5.2.1. Longer timeline and high cost associated with development of pneumococcal vaccines
         5.3. Opportunities
                5.3.1. Development of multivalent conjugated vaccines with different serotypes
         5.4. Trends
                5.4.1. Public-Private Partnerships

    6. Global Pneumococcal Vaccines Market Analysis, by Product Type
         6.1. Introduction
         6.2. Global Pneumococcal Vaccines Market Value Share Analysis, by Product Type
         6.3. Pneumococcal Vaccines Market Analysis, by Product Type 
                6.3.1. Synflorix
                         6.3.1.1. Pediatric
                         6.3.1.2. Adult
                6.3.2. Prevenar-13
                         6.3.2.1. Pediatric
                         6.3.2.2. Adult
                6.3.3. PCV 13 (pipeline)
                         6.3.3.1. Pediatric
                         6.3.3.2. Adult
                6.3.4. V114 (Merck)
                         6.3.4.1. Pediatric
                         6.3.4.2. Adult
                6.3.5. PCV-20 (Pfizer)
                         6.3.5.1. Pediatric
                         6.3.5.2. Adult
                6.3.6. PCV-10 (SII)
                         6.3.6.1. Pediatric
                         6.3.6.2. Adult
                6.3.7. PPSV- 23
                         6.3.7.1. Pediatric
                         6.3.7.2. Adult

    7. Global Pneumococcal Vaccines Market Analysis, by Distribution Channel
         7.1. Introduction
         7.2. Global Pneumococcal Vaccines Market Value Share Analysis, by Distribution Channel
         7.3. Pneumococcal Vaccines Market Analysis, by Distribution Channel
                7.3.1. Wholesalers
                7.3.2. Specialized Companies 
                7.3.3. Public Authorities 
                7.3.4. Others

    8. Global Pneumococcal Vaccines Market Analysis, by Sector
         8.1. Introduction
         8.2. Global Pneumococcal Vaccines Market Value Share Analysis, by Sector
         8.3. Pneumococcal Vaccines Market Analysis, by Sector
                8.3.1. Public
                8.3.2. Private

    9. U.S. Pneumococcal Vaccines Market Analysis
         9.1. U.S. Pneumococcal Vaccines Market Value Share Analysis, by Product Type
         9.2. U.S. Pneumococcal Vaccines Market Forecast, by Product Type
                9.2.1. Prevanar-13
                9.2.2. V114
                9.2.3. PCV-20
                9.2.4. Pneumovax-23
         9.3. U.S. Pneumococcal Vaccines Market Value Share Analysis, by Distribution Channel
         9.4. U.S. Pneumococcal Vaccines Market Forecast, by Distribution Channel
                9.4.1. Wholesalers
                9.4.2. Specialized Companies 
                9.4.3. Public Authorities 
                9.4.4. Others 
         9.5. U.S. Pneumococcal Vaccines Market Value Share Analysis, by Sector
         9.6. U.S. Pneumococcal Vaccines Market Forecast, by Sector
                9.6.1. Private
                9.6.2. Public
         10. Canada Pneumococcal Vaccines Market Analysis

    10.1. Canada Pneumococcal Vaccines Market Value Share Analysis, by Product Type
         10.2. Canada Pneumococcal Vaccines Market Forecast, by Product Type
                10.2.1. Prevenar-13
                10.2.2. Synflorix 
                10.2.3. V-114 
                10.2.4. Pneumo - 23
                10.2.5. Pnuemovax-23
         10.3. Canada Pneumococcal Vaccines Market Value Share Analysis, by Distribution Channel
         10.4. Canada Pneumococcal Vaccines Market Forecast, by Distribution Channel
                10.4.1. Wholesalers
                10.4.2. Specialized Companies 
                10.4.3. Public Authorities 
                10.4.4. Others 
         10.5. Canada Pneumococcal Vaccines Market Value Share Analysis, by Sector
         10.6. Canada Pneumococcal Vaccines Market Forecast, by Sector
                10.6.1. Private
                10.6.2. Public

    11. Germany Pneumococcal Vaccines Market Analysis
         11.1. Germany Pneumococcal Vaccines Market Value Share Analysis, by Product Type
         11.2. Germany Pneumococcal Vaccines Market Forecast, by Product Type
                11.2.1. Prevenar-13
                11.2.2. Synflorix 
                11.2.3. V-114 
                11.2.4. PCV-20
                11.2.5. Pnuemovax-23
         11.3. Germany Pneumococcal Vaccines Market Value Share Analysis, by Distribution Channel
         11.4. Germany Pneumococcal Vaccines Market Forecast, by Distribution Channel
                11.4.1. Wholesalers
                11.4.2. Specialized Companies 
                11.4.3. Public Authorities 
                11.4.4. Others 
         11.5. Germany Pneumococcal Vaccines Market Value Share Analysis, by Sector
         11.6. Germany Pneumococcal Vaccines Market Forecast, by Sector
                11.6.1. Private
                11.6.2. Public

    12. U.K. Pneumococcal Vaccines Market Analysis
         12.1. U.K. Pneumococcal Vaccines Market Value Share Analysis, by Product Type
         12.2. U.K. Pneumococcal Vaccines Market Forecast, by Product Type
                12.2.1. Prevenar-13
                12.2.2. Synflorix 
                12.2.3. V-114 
                12.2.4. PCV-20
                12.2.5. Pnuemovax-23
         12.3. U.K. Pneumococcal Vaccines Market Value Share Analysis, by Distribution Channel
         12.4. U.K. Pneumococcal Vaccines Market Forecast, by Distribution Channel
                12.4.1. Wholesalers
                12.4.2. Specialized Companies 
                12.4.3. Public Authorities 
                12.4.4. Others 
         12.5. U.K. Pneumococcal Vaccines Market Value Share Analysis, by Sector
         12.6. U.K. Pneumococcal Vaccines Market Forecast, by Sector
                12.6.1. Private
                12.6.2. Public

    13. France Pneumococcal Vaccines Market Analysis
         13.1. France Pneumococcal Vaccines Market Value Share Analysis, by Product Type
         13.2. France Pneumococcal Vaccines Market Forecast, by Product Type
                13.2.1. Prevenar-13
                13.2.2. Synflorix 
                13.2.3. V-114 
                13.2.4. PCV-20
                13.2.5. Pnuemovax-23
         13.3. France Pneumococcal Vaccines Market Value Share Analysis, by Distribution Channel
         13.4. France Pneumococcal Vaccines Market Forecast, by Distribution Channel
                13.4.1. Wholesalers
                13.4.2. Specialized Companies 
                13.4.3. Public Authorities 
                13.4.4. Others 
         13.5. France Pneumococcal Vaccines Market Value Share Analysis, by Sector
         13.6. France Pneumococcal Vaccines Market Forecast, by Sector
                13.6.1. Private
                13.6.2. Public

    14. Italy Pneumococcal Vaccines Market Analysis
         14.1. Italy Pneumococcal Vaccines Market Value Share Analysis, by Product Type
         14.2. Italy Pneumococcal Vaccines Market Forecast, by Product Type
                14.2.1. Prevenar-13
                14.2.2. Synflorix 
                14.2.3. V-114 
                14.2.4. PCV-20
                14.2.5. Pnuemovax-23
         14.3. Italy Pneumococcal Vaccines Market Value Share Analysis, by Distribution Channel
         14.4. Italy Pneumococcal Vaccines Market Forecast, by Distribution Channel
                14.4.1. Wholesalers
                14.4.2. Specialized Companies 
                14.4.3. Public Authorities 
                14.4.4. Others 
         14.5. Italy Pneumococcal Vaccines Market Value Share Analysis, by Sector
         14.6. Italy Pneumococcal Vaccines Market Forecast, by Sector
                14.6.1. Private
                14.6.2. Public

    15. Spain Pneumococcal Vaccines Market Analysis
         15.1. Spain Pneumococcal Vaccines Market Value Share Analysis, by Product Type
         15.2. Spain Pneumococcal Vaccines Market Forecast, by Product Type
                15.2.1. Prevenar-13
                15.2.2. Synflorix 
                15.2.3. V-114 
                15.2.4. PCV-20
                15.2.5. Pnuemovax-23
         15.3. Spain Pneumococcal Vaccines Market Value Share Analysis, by Distribution Channel
         15.4. Spain Pneumococcal Vaccines Market Forecast, by Distribution Channel
                15.4.1. Wholesalers
                15.4.2. Specialized Companies 
                15.4.3. Public Authorities 
                15.4.4. Others 
         15.5. Spain Pneumococcal Vaccines Market Value Share Analysis, by Sector
         15.6. Spain Pneumococcal Vaccines Market Forecast, by Sector
                15.6.1. Private
                15.6.2. Public

    16. Belgium Pneumococcal Vaccines Market Analysis
         16.1. Belgium Pneumococcal Vaccines Market Value Share Analysis, by Product Type
         16.2. Belgium Pneumococcal Vaccines Market Forecast, by Product Type
                16.2.1. Prevenar-13
                16.2.2. Synflorix 
                16.2.3. V-114 
                16.2.4. PCV-20
                16.2.5. Pnuemovax-23
         16.3. Belgium Pneumococcal Vaccines Market Value Share Analysis, by Distribution Channel
         16.4. Belgium Pneumococcal Vaccines Market Forecast, by Distribution Channel
                16.4.1. Wholesalers
                16.4.2. Specialized Companies 
                16.4.3. Public Authorities 
                16.4.4. Others 
         16.5. Belgium Pneumococcal Vaccines Market Value Share Analysis, by Sector
         16.6. Belgium Pneumococcal Vaccines Market Forecast, by Sector
                16.6.1. Private
                16.6.2. Public

    17. India Pneumococcal Vaccines Market Analysis
         17.1. India Pneumococcal Vaccines Market Value Share Analysis, by Product Type
         17.2. India Pneumococcal Vaccines Market Forecast, by Product Type
                17.2.1. Prevenar-13
                17.2.2. Synflorix 
                17.2.3. SIIL PCV-10
                17.2.4. PCV-20
                17.2.5. Pnuemovax-23
         17.3. India Pneumococcal Vaccines Market Value Share Analysis, by Distribution Channel
         17.4. India Pneumococcal Vaccines Market Forecast, by Distribution Channel
                17.4.1. Wholesalers
                17.4.2. Specialized Companies 
                17.4.3. Public Authorities 
                17.4.4. Others 
         17.5. India Pneumococcal Vaccines Market Value Share Analysis, by Sector
         17.6. India Pneumococcal Vaccines Market Forecast, by Sector
                17.6.1. Private
                17.6.2. Public
    18. China Pneumococcal Vaccines Market Analysis
         18.1. China Pneumococcal Vaccines Market Value Share Analysis, by Product Type
         18.2. China Pneumococcal Vaccines Market Forecast, by Product Type
                18.2.1. Prevenar-13
                18.2.2. PCV 13 (pipeline)
                18.2.3. PPSV 23
         18.3. China Pneumococcal Vaccines Market Value Share Analysis, by Distribution Channel
         18.4. China Pneumococcal Vaccines Market Forecast, by Distribution Channel
                18.4.1. Wholesalers
                18.4.2. Specialized Companies 
                18.4.3. Public Authorities 
                18.4.4. Others 
         18.5. China Pneumococcal Vaccines Market Value Share Analysis, by Sector
         18.6. China Pneumococcal Vaccines Market Forecast, by Sector
                18.6.1. Private
                18.6.2. Public

    19. Japan Pneumococcal Vaccines Market Analysis
         19.1. Japan Pneumococcal Vaccines Market Value Share Analysis, by Product Type
         19.2. Japan Pneumococcal Vaccines Market Forecast, by Product Type
                19.2.1. Prevenar-13
                19.2.2. Synflorix
                19.2.3. PPSV 23
         19.3. Japan Pneumococcal Vaccines Market Value Share Analysis, by Distribution Channel
         19.4. Japan Pneumococcal Vaccines Market Forecast, by Distribution Channel
                19.4.1. Wholesalers
                19.4.2. Specialized Companies 
                19.4.3. Public Authorities 
                19.4.4. Others 
         19.5. Japan Pneumococcal Vaccines Market Value Share Analysis, by Sector
         19.6. Japan Pneumococcal Vaccines Market Forecast, by Sector
                19.6.1. Private
                19.6.2. Public

    20. Australia Pneumococcal Vaccines Market Analysis
         20.1. Australia Pneumococcal Vaccines Market Value Share Analysis, by Product Type
         20.2. Australia Pneumococcal Vaccines Market Forecast, by Product Type
                20.2.1. Prevenar-13
                20.2.2. Synflorix
                20.2.3. V114
                20.2.4. Pnuemovax-23
         20.3. Australia Pneumococcal Vaccines Market Value Share Analysis, by Distribution Channel
         20.4. Australia Pneumococcal Vaccines Market Forecast, by Distribution Channel
                20.4.1. Wholesalers
                20.4.2. Specialized Companies 
                20.4.3. Public Authorities 
                20.4.4. Others 
         20.5. Australia Pneumococcal Vaccines Market Value Share Analysis, by Sector
         20.6. Australia Pneumococcal Vaccines Market Forecast, by Sector
                20.6.1. Private
                20.6.2. Public

    21. New Zealand Pneumococcal Vaccines Market Analysis
         21.1. New Zealand Pneumococcal Vaccines Market Value Share Analysis, by Product Type
         21.2. New Zealand Pneumococcal Vaccines Market Forecast, by Product Type
                21.2.1. Prevenar-13
                21.2.2. Synflorix
                21.2.3. Pnuemovax-23
         21.3. New Zealand Pneumococcal Vaccines Market Value Share Analysis, by Distribution Channel
         21.4. New Zealand Pneumococcal Vaccines Market Forecast, by Distribution Channel
                21.4.1. Wholesalers
                21.4.2. Specialized Companies 
                21.4.3. Public Authorities 
                21.4.4. Others 
         21.5. New Zealand Pneumococcal Vaccines Market Value Share Analysis, by Sector
         21.6. New Zealand Pneumococcal Vaccines Market Forecast, by Sector
                21.6.1. Private
                21.6.2. Public

    22. Brazil Pneumococcal Vaccines Market Analysis
         22.1. Brazil Pneumococcal Vaccines Market Value Share Analysis, by Product Type
         22.2. Brazil Pneumococcal Vaccines Market Forecast, by Product Type
                22.2.1. Prevenar-13
                22.2.2. Synflorix
                22.2.3. Pnuemovax-23
         22.3. Brazil Pneumococcal Vaccines Market Value Share Analysis, by Distribution Channel
         22.4. Brazil Pneumococcal Vaccines Market Forecast, by Distribution Channel
                22.4.1. Wholesalers
                22.4.2. Specialized Companies 
                22.4.3. Public Authorities 
                22.4.4. Others 
         22.5. Brazil Pneumococcal Vaccines Market Value Share Analysis, by Sector
         22.6. Brazil Pneumococcal Vaccines Market Forecast, by Sector
                22.6.1. Private
                22.6.2. Public

    23. Mexico Pneumococcal Vaccines Market Analysis
         23.1. Mexico Pneumococcal Vaccines Market Value Share Analysis, by Product Type
         23.2. Mexico Pneumococcal Vaccines Market Forecast, by Product Type
                23.2.1. Prevenar-13
                23.2.2. Synflorix
                23.2.3. Pnuemovax-23
         23.3. Mexico Pneumococcal Vaccines Market Value Share Analysis, by Distribution Channel
         23.4. Mexico Pneumococcal Vaccines Market Forecast, by Distribution Channel
                23.4.1. Wholesalers
                23.4.2. Specialized Companies 
                23.4.3. Public Authorities 
                23.4.4. Others 
         23.5. Mexico Pneumococcal Vaccines Market Value Share Analysis, by Sector
         23.6. Mexico Pneumococcal Vaccines Market Forecast, by Sector
                23.6.1. Private
                23.6.2. Public

    24. Rest of the World Pneumococcal Vaccines Market Analysis
         24.1. Rest of the World Pneumococcal Vaccines Market Value Share Analysis, by Product Type
         24.2. Rest of the World Pneumococcal Vaccines Market Forecast, by Product Type
                24.2.1. Prevenar-13
                24.2.2. Synflorix
                24.2.3. V-114
                24.2.4. PCV-20
                24.2.5. PCV-10 (SII)
                24.2.6. Pnuemovax-23
         24.3. Rest of the World Pneumococcal Vaccines Market Value Share Analysis, by Distribution Channel
         24.4. Rest of the World Pneumococcal Vaccines Market Forecast, by Distribution Channel
                24.4.1. Wholesalers
                24.4.2. Specialized Companies 
                24.4.3. Public Authorities 
                24.4.4. Others 
         24.5. Rest of the World Pneumococcal Vaccines Market Value Share Analysis, by Sector
         24.6. Rest of the World Pneumococcal Vaccines Market Forecast, by Sector
                24.6.1. Private
                24.6.2. Public
         24.7. Rest of the World Pneumococcal Vaccines Market Forecast, by Region

    25. Competition Landscape
         25.1. Global Pneumococcal Vaccines Market Share Analysis, by Company (2017)
         25.2. Company Profiles
                25.2.1. Pfizer, Inc.
                25.2.2. Merck & Co., Inc.
                25.2.3. SK Chemicals
                25.2.4. Serum Institute of India Pvt. Ltd.
                25.2.5. Chengdu Institute of Biological Products Co., Ltd.
                25.2.6. GlaxoSmithKline plc
                25.2.7. Sanofi
                25.2.8. Walvax Biotechnology Co., Ltd.

    List of Tables

    TABLE 1 Global Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
    TABLE 2 Global Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    TABLE 3 Global Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Sector, 2016–2026
    TABLE 4 U.S. Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
    TABLE 5 U.S. Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
    TABLE 6 U.S. Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    TABLE 7 U.S. Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Sector, 2016–2026
    TABLE 8 Canada Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
    TABLE 9 Canada Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
    TABLE 10 Canada Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    TABLE 11 Canada Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Sector, 2016–2026
    TABLE 12 Germany Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
    TABLE 13 Germany Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
    TABLE 14 Germany Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    TABLE 15 Germany Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Sector, 2016–2026
    TABLE 16 U.K. Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
    TABLE 17 U.K. Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
    TABLE 18 U.K. Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    TABLE 19 U.K. Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Sector, 2016–2026
    TABLE 20 France Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
    TABLE 21 France Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
    TABLE 22 France Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    TABLE 23 France Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Sector, 2016–2026
    TABLE 24 Italy Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
    TABLE 25 Italy Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
    TABLE 26 Italy Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    TABLE 27 Italy Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Sector, 2016–2026
    TABLE 28 Spain Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
    TABLE 29 Spain Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
    TABLE 30 Spain Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    TABLE 31 Italy Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Sector, 2016–2026
    TABLE 32 Belgium Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
    TABLE 33 Belgium Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
    TABLE 34 Belgium Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    TABLE 35 Belgium Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Sector, 2016–2026
    TABLE 36 India Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
    TABLE 37 India Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
    TABLE 38 India Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    TABLE 39 India Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Sector, 2016–2026
    TABLE 40 China Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
    TABLE 41 China Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
    TABLE 42 China Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    TABLE 43 China Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Sector, 2016–2026
    TABLE 44 Japan Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
    TABLE 45 Japan Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
    TABLE 46 Japan Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    TABLE 47 Japan Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Sector, 2016–2026
    TABLE 48 Australia Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
    TABLE 49 Australia Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
    TABLE 50 Australia Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    TABLE 51 Australia Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Sector, 2016–2026
    TABLE 52 New Zealand Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
    TABLE 53 New Zealand Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
    TABLE 54 New Zealand Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    TABLE 55 New Zealand Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Sector, 2016–2026
    TABLE 56 Brazil Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
    TABLE 57 Brazil Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
    TABLE 58 Brazil Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    TABLE 59 Brazil Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Sector, 2016–2026
    TABLE 60 Mexico Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
    TABLE 61 Mexico Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
    TABLE 62 Mexico Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    TABLE 63 Mexico Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Sector, 2016–2026
    TABLE 64 Rest of the World (RoW) Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
    TABLE 65 Rest of the World (RoW) Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
    TABLE 66 Rest of the World (RoW) Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    TABLE 67 Rest of the World (RoW) Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Sector, 2016–2026
    TABLE 68 Global Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Region, 2016–2026
    TABLE 69 North America Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Country, 2016–2026
    TABLE 70 Europe Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
    TABLE 71 Asia Pacific Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
    TABLE 72 Latin America Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026

    List of Figures

    FIG. 1 Global Pneumococcal Vaccines Market Value (US$ Mn) Forecast, 2016–2026
    FIG. 2 Global Pneumococcal Vaccines Market Value Share (%), by Product Type (2017)
    FIG. 3 Global Pneumococcal Vaccines Market Value Share (%), by Sector (2017)
    FIG. 4 Global Pneumococcal Vaccines Market Value Share (%), by Distribution Channel (2017)
    FIG. 5 Global Pneumococcal Vaccines Market Value Share (%), by Product Type, 2018 and 2026
    FIG. 6 Global Pneumococcal Vaccines Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by 10-Valent, 2016–2026
    FIG. 7 Global Pneumococcal Vaccines Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by 10-Valent (pipeline), 2016–2026
    FIG. 8 Global Pneumococcal Vaccines Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by 13-Valent, 2016–2026
    FIG. 9 Global Pneumococcal Vaccines Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by 13-Valent (pipeline), 2016–2026
    FIG. 10 Global Pneumococcal Vaccines Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by 15-Valent (pipeline), 2016–2026
    FIG. 11 Global Pneumococcal Vaccines Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by 20-Valent (pipeline), 2016–2026
    FIG. 12 Global Pneumococcal Vaccines Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by 23-Valent, 2016–2026
    FIG. 13 Global Pneumococcal Vaccines Market Value Share (%), by Distribution Channel, 2018 and 2026
    FIG. 14 Global Pneumococcal Vaccines Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Wholesalers, 2016–2026
    FIG. 15 Global Pneumococcal Vaccines Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Specialized Companies, 2016–2026
    FIG. 16 Global Pneumococcal Vaccines Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Public Authorities, 2016–2026
    FIG. 17 Global Pneumococcal Vaccines Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2016–2026
    FIG. 18 Global Pneumococcal Vaccines Market Value Share (%), by Sector, 2018 and 2026
    FIG. 19 Global Pneumococcal Vaccines Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Public, 2016–2026
    FIG. 20 Global Pneumococcal Vaccines Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Private, 2016–2026
    FIG. 21 U.S. Pneumococcal Vaccines Market Value Share (%), by Product Type, 2018 and 2026
    FIG. 22 U.S. Pneumococcal Vaccines Market Value Share (%), by Distribution Channel, 2018 and 2026
    FIG. 23 U.S. Pneumococcal Vaccines Market Value Share (%), by Sector, 2018 and 2026
    FIG. 24 Canada Pneumococcal Vaccines Market Value Share (%), by Product Type, 2018 and 2026
    FIG. 25 Canada Pneumococcal Vaccines Market Value Share (%), by Distribution Channel, 2018 and 2026
    FIG. 26 Canada Pneumococcal Vaccines Market Value Share (%), by Sector, 2018 and 2026
    FIG. 27 Germany Pneumococcal Vaccines Market Value Share (%), by Product Type, 2018 and 2026
    FIG. 28 Germany Pneumococcal Vaccines Market Value Share (%), by Distribution Channel, 2018 and 2026
    FIG. 29 Germany Pneumococcal Vaccines Market Value Share (%), by Sector, 2018 and 2026
    FIG. 30 U.K. Pneumococcal Vaccines Market Value Share (%), by Product Type, 2018 and 2026
    FIG. 31 U.K. Pneumococcal Vaccines Market Value Share (%), by Distribution Channel, 2018 and 2026
    FIG. 32 U.K. Pneumococcal Vaccines Market Value Share (%), by Sector, 2018 and 2026
    FIG. 33 France Pneumococcal Vaccines Market Value Share (%), by Product Type, 2018 and 2026
    FIG. 34 France Pneumococcal Vaccines Market Value Share (%), by Distribution Channel, 2018 and 2026
    FIG. 35 France Pneumococcal Vaccines Market Value Share (%), by Sector, 2018 and 2026
    FIG. 36 Italy Pneumococcal Vaccines Market Value Share (%), by Product Type, 2018 and 2026
    FIG. 37 Italy Pneumococcal Vaccines Market Value Share (%), by Distribution Channel, 2018 and 2026
    FIG. 38 Italy Pneumococcal Vaccines Market Value Share (%), by Sector, 2018 and 2026
    FIG. 39 Spain Pneumococcal Vaccines Market Value Share (%), by Product Type, 2018 and 2026
    FIG. 40 Spain Pneumococcal Vaccines Market Value Share (%), by Distribution Channel, 2018 and 2026
    FIG. 41 Spain Pneumococcal Vaccines Market Value Share (%), by Sector, 2018 and 2026
    FIG. 42 Belgium Pneumococcal Vaccines Market Value Share (%), by Product Type, 2018 and 2026
    FIG. 43 Belgium Pneumococcal Vaccines Market Value Share (%), by Distribution Channel, 2018 and 2026
    FIG. 44 Belgium Pneumococcal Vaccines Market Value Share (%), by Sector, 2018 and 2026
    FIG. 45 India Pneumococcal Vaccines Market Value Share (%), by Product Type, 2018 and 2026
    FIG. 46 India Pneumococcal Vaccines Market Value Share (%), by Distribution Channel, 2018 and 2026
    FIG. 47 India Pneumococcal Vaccines Market Value Share (%), by Sector, 2018 and 2026
    FIG. 48 China Pneumococcal Vaccines Market Value Share (%), by Product Type, 2018 and 2026
    FIG. 49 China Pneumococcal Vaccines Market Value Share (%), by Distribution Channel, 2018 and 2026
    FIG. 50 China Pneumococcal Vaccines Market Value Share (%), by Sector, 2018 and 2026
    FIG. 51 Japan Pneumococcal Vaccines Market Value Share (%), by Product Type, 2018 and 2026
    FIG. 52 Japan Pneumococcal Vaccines Market Value Share (%), by Distribution Channel, 2018 and 2026
    FIG. 53 Japan Pneumococcal Vaccines Market Value Share (%), by Sector, 2018 and 2026
    FIG. 54 New Zealand Pneumococcal Vaccines Market Value Share (%), by Product Type, 2018 and 2026
    FIG. 55 Australia Pneumococcal Vaccines Market Value Share (%), by Distribution Channel, 2018 and 2026
    FIG. 56 Australia Pneumococcal Vaccines Market Value Share (%), by Sector, 2018 and 2026
    FIG. 57 New Zealand Pneumococcal Vaccines Market Value Share (%), by Product Type, 2018 and 2026
    FIG. 58 New Zealand Pneumococcal Vaccines Market Value Share (%), by Distribution Channel, 2018 and 2026
    FIG. 59 New Zealand Pneumococcal Vaccines Market Value Share (%), by Sector, 2018 and 2026
    FIG. 60 Brazil Pneumococcal Vaccines Market Value Share (%), by Product Type, 2018 and 2026
    FIG. 61 Brazil Pneumococcal Vaccines Market Value Share (%), by Distribution Channel, 2018 and 2026
    FIG. 62 Brazil Pneumococcal Vaccines Market Value Share (%), by Sector, 2018 and 2026
    FIG. 63 Mexico Pneumococcal Vaccines Market Value Share (%), by Product Type, 2018 and 2026
    FIG. 64 Mexico Pneumococcal Vaccines Market Value Share (%), by Distribution Channel, 2018 and 2026
    FIG. 65 Mexico Pneumococcal Vaccines Market Value Share (%), by Sector, 2018 and 2026
    FIG. 66 Rest of the World (RoW) Pneumococcal Vaccines Market Value Share (%), by Product Type, 2018 and 2026
    FIG. 67 Rest of the World (RoW) Pneumococcal Vaccines Market Value Share (%), by Distribution Channel, 2018 and 2026
    FIG. 68 Rest of the World (RoW) Pneumococcal Vaccines Market Value Share (%), by Sector, 2018 and 2026
    FIG. 69 Global Pneumococcal Vaccines Market Share (%) and Market Share Range (%), by Company, 2017

Copyright © Transparency Market Research, Inc. All Rights reserved